U.S. DHHS. FDA-Approved HIV Medicines [Internet]. AIDSinfo. 2020 [cited 2020 Apr 28]. Available from: https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines
Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, et al. International AIDS Society Global Scientific Strategy: towards an HIV Cure 2016. Nat Med. 2016;22(8):839–50.
Freedberg KA, Sax PE. Improving on effective antiretroviral therapy: how good will a cure have to be? J Med Ethics. 2017;43(2):71–3.
Granich R, Gupta S, Hall I, Aberle-Grasse J, Hader S, Mermin J. Status and methodology of publicly available national HIV care continua and 90-90-90 targets: a systematic review. PLOS Med. 2017;14(4):e1002253.
TAG. Research Toward a Cure Trials [Internet]. 2021. Available from: http://www.treatmentactiongroup.org/cure/trials.
Lo B, Grady C. Ethical Considerations in HIV Cure Research: Points to Consider. Curr Opin HIV AIDS. 2013;8(3):243–9.
Eyal N, Holtzman LG, Deeks SG. Ethical issues in HIV remission trials. Curr Opin HIV AIDS. 2018;13(5):422–7.
Dresser R. First-in-human HIV-remission studies: reducing and justifying risk. J Med Ethics. 2017;43(2):78–81.
Julg B, Dee L, Ananworanich J, Barouch D, Bar K, Caskey M, et al. Recommendations for analytical treatment interruptions in HIV research trials. Report of a consensus meeting. Lancet HIV. 2019;6(4):e259–68.
Eyal N, Lipsitch M, Bärnighausen T, Wikler D. Risk to study nonparticipants: a procedural approach. PNAS. 2018;115(32):8051–3.
Eyal N, Deeks SG. Risk to nonparticipants in HIV remission studies with treatment interruption: a symposium. J Infect Dis. 2019;220(Suppl 1):1–4.
Dawson L. Human immunodeficiency virus transmission risk in analytical treatment interruption studies: relational factors and moral responsibility. J Infect Dis. 2019;220(Suppl 1):S12-15.
Peluso MJ, Dee L, Campbell D, Taylor J, Hoh R, Rutishauser RL, et al. A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption. J Virus Erad. 2020;6:34–7.
Lelièvre J-D, Hocqueloux L. Unintended HIV-1 transmission to a sex partner in a study of a therapeutic vaccine candidate. J Infect Dis. 2019;16:4–5.
Ugarte A, Romero Y, Tricas A, Casado C, Garcia F, Leal L. Unintended HIV-1 infection during analytical treatment interruption. J Infect Dis. 2019;221(10):1740–2.
Sugarman J. HIV Cure Research. Expanding the ethical considerations. Ann Intern Med. 2013;159:9–11.
Henderson GE. The ethics of HIV “cure” research: what can we learn from consent forms? AIDS Res Hum Retroviruses. 2014;31(1):1–14.
Bromwich D, Millum JR. Informed consent to HIV cure research. J Med Ethics. 2017;43(2):108–13.
Dubé K, Taylor J, Sylla L, Evans D, Dee L, Burton A, et al. “Well, it’s the risk of the unknown… right?”: a qualitative study of perceived risks and benefits of HIV cure research in the United States. PLoS ONE. 2017;12(1):1–23.
Dubé K, Dee L, Evans D, Sylla L, Taylor J, Brown B, et al. Perceptions of equipoise, risk—benefit ratios, and “otherwise healthy volunteers” in the context of early-phase HIV cure research in the United States: a qualitative inquiry. J Empir Res Hum Res Ethics. 2017;13(1):1–15.
Eyal N, Holtzman LG. Invited Commentary on Dubé et al. (Perceptions of equipoise, risk/benefit ratios, and “otherwise healthy volunteers” in the context of early-phase HIV cure research in the United States—a qualitative inquiry): are HIV-Infected Candidates for Participat. J Empir Res Hum Res Ethics. 2018;13(1):18–22.
Dubé K, Sylla L, Dee L. Reply to Commentary: “Are HIV-infected candidates for participation in risky cure- related studies otherwise healthy”. J Empir Res Hum Res Ethics. 2017;13(1):1–3.
Dubé K, Dee L. Willingness to risk death endpoint in HIV cure-related research with otherwise healthy volunteers is misleading. J Virus Erad. 2020;6:81–4.
Hare C. Risk and radical uncertainty in HIV research. J Med Ethics. 2017;43(2):87–9.
Gilbertson A, Kelly EP, Rennie S, Henderson GE, Kuruc JD, Tucker JD. Indirect benefits in HIV cure clinical research: a qualitative analysis. AIDS Res Hum Retroviruses. 2019;35(1):100–7.
Rennie S, Day S, Mathews A, Gilbertson A, Luseno W, Tucker J, et al. The role of inclusion benefits in ethics committee assessment of research studies. Ethics Hum Res. 2019;41(3):13–22.
Brown B, Galea JT, Davidson P, Khoshnood K. Transparency of participant incentives in HIV research. Lancet HIV. 2016;3(10):e456–7.
Rossouw T, Tucker JD, van Zyl GU, Sikwesi K, Godfrey C. Barriers to HIV remission research in low- and middle-income countries. J Int AIDS Soc. 2017;20(1):1–9.
Ndungu T, McCune JM, Deeks SG. Why and where an HIV cure is needed and how it might be achieved. Nature. 2019;576(April):397–405.
Muccini C, Crowell TA, Kroon E, Sacdalan C, Ramautarsing R, Seekaew P, et al. Leveraging early HIV diagnosis and treatment in thailand to conduct HIV cure research. AIDS Res Ther. 2019;16(25):1–8.
Tucker JD, Gilbertson A, Lo Y-R, Vitória M. Implications of prioritizing HIV cure: new momentum to overcome old challenges in HIV. BMC Infect Dis. 2016;16(1):109.
Day S, Blumberg M, Vu T, Zhao Y, Rennie S, Tucker JD. Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence. J Int AIDS Soc. 2018;21(S7):e25174.
Lo Y-R, Chu C, Ananworanich J, Excler J-L, Tucker JD. Stakeholder engagement in HIV cure research: lessons learned from other HIV interventions and the way forward. AIDS Patient Care STDS. 2015;29(7):389–99.
Karris MY, Dubé K, Moore AA. What lessons it might teach us? Community engagement in HIV research. Curr Opin HIV AIDS. 2019;12(2):142–9.
Lau J, Smith M, Allan B, Dubé K, Young A, Power J. Time for revolution? Enhancing meaningful involvement of people living with HIV in HIV cure-focused science. J Virus Erad. 2020;6(4):100018.
Armstrong R, Hall BJ, Doyle J, Waters E. “Scoping the scope” of a cochrane review. J Public Health (Oxf). 2011;33(1):147–50.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.
Peterson C, Kiem H. Cell and gene therapy for HIV cure. Curr Trop Microbiol Immunol. 2018;417:211–8.
DiGiusto DL, Stan R, Krishnan A, Li H, Rossi JJ, Zaia JA. Development of hematopoietic stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical practice. Viruses. 2013;5(11):2898–919.
Ward AR, Mota TM, Jones RB. Immunological approaches to HIV cure. Semin Immunol. 2020. https://doi.org/10.1016/j.smim.2020.101412.
Carcelain G, Autran B. Immune interventions in HIV infection. Immunol Rev. 2013;254(1):355–71.
Ananworanich J, Dubé K, Chomont N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr Opin HIV AIDS. 2015;10(1):18–28.
Margolis DM, Garcia JV, Hazuda DJ, Haynes BF. Latency reversal and viral clearance to cure HIV-1. Science. 2016;353(6297):aaf6517.
Archin N, Sung J, Garrido C, Soriano-Sarabia N, Margolis D. Eradicating HIV-1 Infection: Seeking to Clear a Persistent Pathogen. Nat Rev Microbiol. 2014;12(11):750–64.
Dubé K, Sylla L, Dee L, Taylor J, Evans D, Bruton C, et al. Research on HIV cure: mapping the ethics landscape. PLoS Med. 2017;14(12):e1002470.
Sugarman J, Lewin SR, Henrich TJ, Rasmussen T. Ethics of ART interruption after stem-cell transplantation. Lancet HIV. 2016;3(1):e8-10.
Stan R, Zaia JA. Practical considerations in gene therapy for HIV cure. Curr HIV/AIDS Rep. 2014;11(1):11–9.
Margolis DM, Hazuda DJ. Combined approaches for HIV cure. Curr Opin HIV AIDS. 2013;8(3):230–5.
Schwarzer R, Gramatica A, Greene WC. Reduce and control: a combinatorial strategy for achieving sustained HIV remissions in the absence of antiretroviral therapy. Viruses. 2019;12(188):1–31.
Ananworanich J, Barré-Sinoussi F. Is it time to abandon single intervention Cure Trials? Lancet HIV. 2015;2(10):e410–1.
Lebbink RJ, Jong DCM De, Wolters F, Kruse EM, Ham PM Van, Wiertz EJHJ, et al. A Combinational CRISPR/Cas9 Gene-Editing Approach Can Halt HIV Replication and Prevent Viral Escape. Nat Publ Gr. 2017;(December 2016):1–10.
Ho Y-C, Siliciano JD. Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection. J Virus Erad. 2015;1(4):229.
Autran B. Toward a cure for HIV: seeking effective therapeutic vaccine strategies. Eur J Immunol. 2015;45(12):3215–21.
Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014;158(5):989–99.
Margolis DM, Koup RA, Ferrari G. HIV antibodies for treatment of HIV infection. Immunol Rev. 2017;275(1):313–23.
UCSD. Last Gift. A University of California San Diego Study. [Internet]. 2018. Available from: http://lastgift.ucsd.edu/
Dubé K, Gianella S, Concha-Garcia S, Little SJ, Kaytes A, Taylor J, et al. Ethical considerations for HIV cure-related research at the end of life. BMC Med Ethics. 2018;19(83):1–16.
Gianella S, Taylor J, Brown TR, Kaytes A, Achim CL, Moore DJ, et al. Can Research at the end of life be a useful tool to advance HIV cure? AIDS. 2017;31:1–4.
Chaillon A, Gianella S, Dellicour S, Rawlings SA, Schlub TE, de Oliveira MF, et al. HIV persists throughout deep tissues with repopulation from multiple anatomical sources. J Clin Invest. 2020;130(4):1699–712.
Pentz RD, Cohen CB, Wicclair M, Devita MA, Flamm AL, Youngner SJ, et al. Ethics guidelines for research with the recently dead. Nat Med. 2005;11(11):1145–9.
Dubé K, Patel H, Concha-Garcia S, Nathan A, Miller B, Kaytes A, et al. Perceptions of next-of-kin/loved ones about last gift study participation at the end of life. Strategies for an HIV Cure. 2018;36(12):1033–46.
Dubé K, Patel H, Concha-Garcia S, Perry KE, Mathur K, Javadi S, et al. Perceptions of next-of-Kin/loved ones about last gift rapid research autopsy study enrolling people with HIV/AIDS at the end-of-life: a qualitative interview study. AIDS Res Hum Retroviruses. 2020;36(12):1033–46.
Javadi SS, Mathur K, Concha-Garcia S, Patel H, Perry K, Lo M, et al. Attitudes and perceptions of next-of-Kin/loved ones toward end-of-life HIV cure-related research: a qualitative focus group study in Southern California. PLoS ONE. 2021;16(5):e0250882.
Prakash K, Gianella S, Dubé K, Taylor J, Lee G, Smith D. Willingness to participate in HIV research at the end of life (EOL). PLoS ONE. 2018;13(7):e0199670.
Brown R, Evans NG. The social value of candidate HIV cures: actualism versus possibilism. J Med Ethics. 2017;43(1):118–23.
Lewin SR, Attoye T, Bansbach C, Doehle B, Dube K, Dybul M, et al. Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV. 2021;8(1):e42-50.
Sugarman J. Ethics of HIV and hepatitis B cure research. Curr Opin HIV AIDS. 2020;15(3):1–5.
Joffe S, Miller FG. Bench to bedside. mapping the moral terrain of clinical research. Hastings Cent Rep. 2008;38(2):30–42.
Beacroft L, Hallett T. The potential impact of a “curative intervention” for HIV: a modeling study. Glob Health Res Policy. 2019;4:2. https://doi.org/10.1186/s41256-019-0107-1.
Dubé K, Auerbach JD, Stirratt MJ, Gaist P. Applying the behavioural and social sciences research (BSSR) functional framework to HIV cure research. J Int AIDS Soc. 2019;22:e25404.
Emanuel EJ, Wendler D, Killen J, Grady C. What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis. 2004;189:930–7.
Pitler L. Ethics of AIDS clinical trials in developing countries: a review. Food Drug Law J. 2016;57:133–53.
Moodley K, Rossouw T, Staunton C, Colvin CJ. Synergies, tensions and challenges in HIV prevention, treatment and cure research: exploratory conversations with HIV experts in South Africa. BMC Med Ethics. 2016;17(1):26.
Henderson GE, Peay HL, Kroon E, Cadigan RJ, Meagher K, Jupimai T, et al. Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. J Med Ethics. 2018;44(4):270–6.
Dubé K, Evans D, Dee L, Sylla L, Taylor J, Weiner BJ, et al. “We need to deploy them very thoughtfully and carefully”: perceptions of analytical treatment interruptions in HIV cure research in the United States. AIDS Res Hum Retroviruses. 2017;34(1):67–79.
Garner SA, Rennie S, Ananworanich J, Dubé K, Margolis DM, Sugarman J, et al. Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. J Virus Erad. 2017;3:82–4.
Lelièvre JD, Hocqueloux L. Unintended HIV-1 transmission to a sex partner in a study of a therapeutic vaccine candidate. J Infect Dis. 2019;220(Suppl 1):S5–6.
Palich R, Ghosn J, Chaillon A, Delobel P, Molina J, Thiebaut R, et al. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial. AIDS. 2019;33(2):279–84.
Dee L, Boone CA, Palm D, Campbell D, Dubé K. Secondary HIV infection and mitigation in cure-related HIV trials during analytical treatment interruptions. J Infect Dis. 2019;220(7):34–7.
Power J, Westle A, Dowsett GW, Lucke J, Tucker JD, Sugarman J, et al. Perceptions of HIV cure research among people living with HIV in Australia. PLoS ONE. 2018;13(8):e0202647.
Power J, Dowsett GW, Westle A, Tucker JD, Hill S, Sugarman J, et al. The Significance and expectations of HIV cure research among people living with HIV in Australia. PLoS ONE. 2020;15(3):e0229733.
Grace D, Chown SA, Kwag M, Steinberg M, Lim E, Gilbert M, et al. Becoming “Undetectable”: longitudinal narratives of Gay Men’s sex lives after a recent HIV diagnosis. AIDS Educ Prev. 2015;27(4):333–49.
Dubé K, Kanazawa JT, Dee L, Taylor J, Campbell DM, Brown BJ, et al. Ethical and practical considrations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related reserch. HIV Res Clin Pract. 2021;22(1):1–17.
Sugarman J. Ethical considerations regarding oral preexposure prophylaxis in HIV prevention trials. Curr Opin HIV AIDS. 2016;11(1):109–15.
Sugarman J, Celum C, Donnell D, Mayer K. Ethical considerations for new HIV prevention trials. Lancet. 2019;6(August):e489–91.
Grimsrud A, Wilkinson L, Eshun-Wilson I, Holmes C, Sikazwe I, Eshun-wilson I. Understanding engagement in HIV programmes: how health services can adapt to ensure no one is left behind. Curr HIV/AIDS Rep. 2020;15(5):458–66.
Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, et al. The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies. J Infect Dis. 2018;218(12):1954–63.
Lau JSY, Smith MZ, Allan B, Martinez C, Power J, Lewin SR, et al. Perspectives on analytical treatment interruptions in people living with HIV and their health care providers in the landscape of HIV cure-focused studies. AIDS Res Hum Retroviruses. 2019;36(4):1–8.
Curno MJ, Rossi S, Hodges-Mameletzis I, Johnston R, Price MA, Heidari S. A Systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies. JAIDS. 2016;71(2):181–8.
Poteat T, Aqil A, Corbett D, Evans D, Dubé K. “I would really want to know that they had my back”: Transgender Women’s Perceptions of HIV Cure-Related Research in the United States. PLoS ONE. 2020;15(12):e0244490.
Dubé K, Kanazawa JT, Campbell C, Boone CA, Maragh-Bass A, Campbell DM, et al. Considerations for increasing racial, ethnic, gender and sexual diversity in HIV cure-related research with analytical treatment interruptions: a qualitative inquiry. AIDS Res Hum Retroviruses. 2021. https://doi.org/10.1089/AID.2021.0023.
Kimmelman J, London AJ. Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med. 2011;8(3):1–5.
Chapman AR. Addressing the ethical challenges of first-in-human trials. J Clin Res Bioeth. 2011;2(4):1–8.
Dubé K, Perry K, Mathur K, Lo M, Javadi S, Patel H, et al. Altruism: scoping review of the literature and future directions for HIV cure-related research. J Virus Erad. 2020;6(4):100008.
Jansen L. The ethics of altruism in clinical research. Hastings Cent Rep. 2009;39(4):26–36.
Eyal N. The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction. J Med Ethics. 2017;43:100–3.
Buchak L. Why High-Risk, Non-expected utility maximising gambles can be rational and beneficial: the case of HIV cure studies. J Med Ethics. 2016;43(2):1–6.
Rid A, Wendler D. A framework for risk-benefit evaluations in biomedical research. Kennedy Inst Ethics J. 2011;21(2):141–79.
Wikler D. Must research benefit human subjects if it is to be permissible? J Med Ethics. 2017;43(2):114–7.
Aarons DE. Exploring the risk/benefit balance in biomedical research: some considerations. Rev Bioét. 2017;25(2):320–7.
Eyal N, Kuritzkes DR. Challenges in clinical trial design for HIV-1 cure research. Lancet. 2013;382(9903):1464–5.
Różyńska J. On the alleged right to participate in high-risk research. Bioethics. 2015;29(7):451–61.
Weijer C. Thinking clearly about research risk: implications of the work of Benjamin Freedman. IRB. 1999;21(6):1–5.
Steel R. Reconceptualising risk—benefit analyses: the case of HIV cure research. J Med Ethics. 2020;46(3):212–9.
Eyal N. How to keep high-risk studies ethical: classifying candidate solutions. J Med Ethics. 2017;43(2):74–7.
Largent E. For love and money: the need to rethink benefits in HIV cure studies. J Med Ethics. 2017;43(2):96–9.
Evans D. An activist’s argument that participant values should guide risk-benefit ratio calculations in HIV cure research. J Med Ethics. 2017;43(2):100–3.
Mehraj V, Ghali P, Ramendra R, Costiniuk C, Lebouché B, Ponte R, et al. The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research. J Virus Erad. 2017;3:212–7.
Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2011;117(10):2791–9.
Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. HIV-1 remission following CCR5 ∆-32/∆-32 haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244–8.
Peay H, Ormsby N, Henderson G, Jupimai T, Rennie S, Siripassorn K, et al. Recommendations from Thai Stakeholders about Protecting HIV Remission ('Cure’) Trial Participants: Report from a Participatory Workshop. Int Health. 2020;12:567–74.
Peluso MJ, Dee L, Shao S, Taylor J, Campbell D, Collins S, et al. Operationalizing HIV cure-related trials with analytic treatment interruptions during the SARS-Cov-2 pandemic: a collaborative approach. Clin Infect Dis. 2020;72(10):ciaa1260.
Peluso MJ, Dee L, Taylor J, Campbell D, Ehm A, Agosto-Rosario M, et al. SARS-Cov-2 vaccination in the context of ongoing HIV cure-related studies. J Acquir Immune Defic Syndr. 2021;84(4):e232–2.
Stecher M, Klein F, Lehmann C, Platten M, Gillor D, Behrens G, et al. Systematic review of the current literature on structured treatment interruptions in HIV-infected patients receiving ART: implications for HIV cure trials. Clin Infect Dis. 2020;70(7):1406–17.
Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. AIDS. 2019;33:773–91.
Dubé K, Hosey L, Starr K, Evans D, Hoffman E, Campbell D, et al. Participant Perspectives in an HIV cure-related trial conducted exclusively in women in the United States: Results from AIDS Clinical Trials Group (ACTG) 5366. AIDS Res Hum Retroviruses. 2020;36(4):268–82.
Perry KE, Dubé K, Concha-Garcia S, Patel H, Kaytes A, Taylor J, et al. "My Death Will Not [Be] in Vain: Testimonials from Last Gift Rapid Research Study Participants Living with HIV at the End of Life. AIDS Res Hum Retroviruses. 2020;36(12):1071–82.
Diepstra KL, Barr L, Palm D, Hogg E, Mollan KR, Henley L, et al. Participant perspectives and experiences entering an intensively monitored antiretroviral pause: results from the AIDS clinical trials group A5345 biomarker study. AIDS Res Hum Retroviruses. 2021;37(6):489–501.
Freshwater W. From early AIDS vaccine to HIV cure research with analytical treatment interruption trials: a study participant testimonial. J Virus Erad. 2019;5(4):231–3.
Hawley C. “Fear overcome by love”: why I participated in HIV cure research. J Virus Erad. 2018;4:248–9.
Brown TR. I Am the Berlin patient: a personal reflection. AIDS Res Hum Retroviruses. 2015;31(1):2–3.
Protière C, Arnold M, Fiorentino M, Fressard L, Leli JD, Mora M, et al. Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study: a discrete choice experiment. J Int AIDS Soc. 2020;23(e25443):1–9.
Shah SK. When to start paediatric testing of the adult HIV cure research agenda? J Med Ethics. 2017;43(2):82–6.
Griffith D, Agwu A. Caring for youth living with HIV across the continuum: turning gaps into opportunities. AIDS Care. 2017;29:1205–11.
Shah SK, Persaud D, Wendler DS, Taylor H, Gay H, Kruger M, et al. Research into a functional cure for HIV in neonates: the need for ethical foresight. Lancet Infect Dis. 2014;14(9):893–8.
Dubé K, Henderson GE, Margolis DM. Framing expectations in early HIV cure research. Trends Microbiol. 2014;22(10):547–9.
Tucker J, Volberding P, Margolis D, Rennie S, Barré-Sinoussi F. Words matter: discussing research towards an HIV cure in research and clinical contexts. JAIDS J Acquir Immune Defic Syndr. 2014;67(3):110–1.
Rennie S, Siedner M, Tucker JD, Moodley K. The ethics of talking about “HIV cure.” BMC Med Ethics. 2015;16:18.
Nie J-B, Gilbertson A, de Malcolm R, Staunton C, van Niekerk A, Tucker JD, et al. Healing without waging war: beyond military metaphors in medicine and HIV cure research. Am J Bioeth. 2016;16(10):3–11.
Dubé K, Luter S, Lesnar B, Newton L, Galea J, Brown B, et al. Use of “eradication” in HIV cure-related research: a public health debate. BMC Public Health. 2018;18:245.
Newton L, Necochea R, Palm D, Taylor J, Barr L, Patel H, et al. Revisiting the “sterilizing cure” terminology: a call for more patient-centred perspectives on HIV cure-related research. J Virus Erad. 2019;5(2):122–4.
Dubé K, Willenberg L, Dee L, Sylla L, Taylor J, Roebuck C, et al. Re-examining the HIV ‘functional cure’ oxymoron: time for precise terminology? J Virus Erad. 2020;6(October):100017.
Bromley E, Mikesell L, Jones F, Khodyakov D. From subject to participant: ethics and the evolving role of community in health research. Am J Public Health. 2015;105(5):900–8.
DAIDS. NIAID Language Guide [Internet]. 2020. p. 25. Available from: https://daidslearningportal.niaid.nih.gov/local/pages/?id=17
Dilmitis S, Edwards O, Hull B, Margolese S, Mason N, Namiba A, et al. Language, identity and HIV: why do we keep talking about the responsible and responsive use of language? Lang Matters JIAS. 2012;15(Suppl 2):2–4.
Annas GJ. Cure research and consent: the Mississippi Baby, Barney Clark, Baby Fae, and Martin Delaney. J Med Ethics. 2017;43:104–7.
Henderson GE, Waltz M, Meagher K, Cadigan RJ, Jupimai T, Phanuphak N, et al. Going off antiretroviral treatment in a closely monitored HIV “cure” trial: longitudinal assessments of acutely diagnosed trial participants and decliners. J Int. 2019;22:e25260.
Henderson GE, Rennie S, Corneli A, Peay HL. Cohorts as collections of bodies and communities of persons: insights from the SEARCH010/RV254 research cohort. Int Health. 2020;12:584–90.
Horng S, Grady C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB. 2003;25(1):11–6.
Miller FG, Brody H. A critique of clinical equipoise. Therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep. 2003;33(3):19–28.
Weinfurt KP, Seils DM, Tzeng JP, Compton KL, Sulmasy DP, Astrow AB, et al. Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Mak. 2008;28(4):575–81.
Staunton C. Informed consent for HIV cure research in South Africa: issues to consider. BMC Med Ethics. 2015;16:3. https://doi.org/10.1186/1472-6939-16-3.
Moodley K, Staunton C, Rossouw T, De Roubaix M, Duby Z. The psychology of “cure”. Unique challenges to consent processes in HIV cure research in South Africa. BMC Med Ethics. 2019;20(9):1–11.
Pan X, Zhang A, Henderson GE, Rennie S, Liu C, Cai W, et al. Traditional, Complementary, and alternative medical cures for HIV: rationale and implications for HIV cure research. Glob Public Health. 2019;14(1):152–60.
Protière C, Fressard L, Mora M, Meyer L, Preau M, Suzan-Monti M, et al. Characterization of physicians that might be reluctant to propose HIV cure-related clinical trials with treatment interruption to their patients? The ANRS-APSEC Study. Vaccines. 2020;8:334.
Lau JS, Smith M, Allan B, Martinez C, Power J, Lewin S, et al. Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies. AIDS Res Ther. 2020;17(65):1–6.
Brion J. The patient-provider relationship as experienced by a diverse sample of highly adherent HIV-infected people. J Assoc Nurses AIDS Care. 2014;25(2):123–34.
Sugarman J, Lavori PW, Boegerfd M, Cainb C, Edson R, Morrisonf V, et al. Evaluating the quality of informed consent. Clin Trials. 2005;2:34–41.
Lavori PW, Wilt TJ, Sugarman J. Quality assurance questionnaire for professionals fails to improve the quality of informed consent. Clin Trials. 2007;4:638–49.
Sauceda JA, Dubé K, Brown B, Pérez AE, Rivas CE, Evans D, et al. Framing a consent form to improve consent understanding and determine how this affects willingness to participate in HIV cure research : an experimental survey study. J Empir Res Hum Res Ethic. 2020;16(1–2):78–87.
Dhilbegovic B. Uncertainty and equipoise: at interplay between epistemology, decision-making and ethics. Am J Med Sci. 2011;342(4):282–9.
IOM. Characterizing Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products—Workshop in Brief. 2017.
Beauchamp T, Childress J. Principles of biomedical ethics. 3rd ed. Oxford: Oxford University Press; 1989. p. 470.
Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA J Am Med Assoc. 2013;283(20):2701–11.
Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee T-H, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014;161(5):319–27.
Henrich TJ, Hanhauser E, Sirignano MN, Li JZ, Lichterfeld M, Marty FM, et al. HIV-1 Rebound following allogeneic stem cell transplantation and treatment interruption. In: CROI. 2014.
Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun T-W, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369(19):1828–35.
Luzuriaga K, Gay H, Siemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett K, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med. 2015;372(8):784–6.
Deakin CT, Alexander IE, Hooker CA, Kerridge IH. Gene therapy researchers’ assessments of risks and perceptions of risk acceptability in clinical trials. Mol Ther. 2013;21(4):806–15.
Dubé K, Barr L, Palm D, Brown B, Taylor J. Putting Participants at the Centre of HIV Cure Research. Lancet HIV. 2019;3018(19):18–9.
FDA. Patient Preference Information - Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption, Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling. 2016.
FDA. The Voice of the Patient. 2014.
Protière C, Spire B, Mora M, Poizot-Martin I, Doumergue M, Morlat P, et al. Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a Multicentre French Survey Using Q Methodology (ANRS-ASPECT). PLoS ONE. 2017;12(11):e0187489.
Dubé K, Eskaf S, Evans D, Sauceda J, Saberi P, Brown B, et al. The dose response: perceptions of people living with HIV in the United States on alternatives to oral daily antiretroviral therapy. AIDS Res Hum Retroviruses. 2019;36(4):324–48.
Dubé K, Campbell DM, Perry KE, Kanazawa JT, Saberi P, Sauceda JA, et al. Reasons people living with HIV might prefer oral daily antiretroviral therapy, long-acting formulations, or future HIV remission options. AIDS Res Hum Retroviruses. 2020;36(12):1054–8.
Safreed-Harmon K, Anderson J, Azzopardi-muscat N, Behrens GMN, Monforte A, Davidovich U, et al. Reorienting health systems to care for people with HIV beyond viral suppression. Lancet HIV. 2019;6(12):e869–77.
Peay H, Henderson G. What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. J Virus Erad. 2015;1(1):51–3.
Dubé K, Simoni J, Louella M, Sylla L, Mohamed ZH, Patel H, et al. Acceptability of cell and gene therapy for curing HIV infection among people living with HIV in the Northwestern United States: a qualitative study. AIDS Res Hum Retroviruses. 2019;35(7):649–59.
Lo Y, Chu C, Ananworanich J, Excler J, Tucker JD. Stakeholder engagement in HIV cure eesearch: lessons learned from other HIV interventions and the way forward. AIDS Patient Care STDS. 2015;29(7):1–11.
UNAIDS, AVAC. Good Participatory Practice Guidelines for Biomedical HIV.
CPTR. Good Participatory Practice Guidelines for TB Drug Trials. 2012.
WHO. Good Participatory Practice Guidelines for Trials of Emerging (and Re-Emerging) Pathogens That Are Likely to Cause Severe Outbreaks in the Near Future and For Which Few or No Medical Countermeasures Exist (GPP-EP). 2016.
Shippee ND, Domecq Garces JP, Prutsky Lopez GJ, Wang Z, Elraiyah TA, Nabhan M, et al. Patient and service user engagement in research: a systematic review and synthesized framework. Heal Expect. 2015;18(5):1151–66.
Kottow MH. Clinical and research ethics as moral strangers. Arch Immunol Ther Exp (Warsz). 2009;57(3):157–64.